than those we admit, 12 admit patients who have an uneventful and brief hospital stay, and remain surprised by the proportion (4%) who experience death within 30 days. 13 This also makes one consider the competing risk of death and nonfatal rehospitalization. Which risk is more concerning? Should we consider the event with the higher financial penalty? Both are important, especially to patients. However, stratifying the risk for death is paramount.
In this issue of Circulation, Lee and colleagues 14 externally tested their 7-day (EHMRG7: Emergency Heart Failure Mortality Risk Grade) and 30-day (EHMRG30) risk score in nearly 2000 patients at 9 hospitals in Ontario, Canada. In comparison with most previous risk-stratification studies, the authors externally tested their original rule in a prospective manner, in a separate cohort of patients, simultaneously determined physician-estimated risk, and performed comprehensive follow-up. This step is critical before an implementation study. It is important to note that a waiver of informed consent facilitated enrollment along the entire spectrum of disease severity. Their patients were older (median 81 years), with 71% having a previous diagnosis of heart failure, and a fair proportion of cardiovascular and noncardiovascular comorbidities. Of these patients, 21% were discharged from the ED. Those patients discharged home had <1.5% 7-day and 3.3% 30-day mortality. Within 7 days, 39 patients died (2%), and by day 30 this rose to 138 patients (7%). Of the 138 deaths, only 17 occurred outside the hospital. They assigned patients into 5 prespecified risk categories: very low, low, intermediate, high, and very high. Patients in the very-low-risk or low-risk (518 patients) categories had 7-day and 30-day mortality rates of 0%. The discrimination for physicianestimated risk (area under the curve=0.71) was improved (area under the curve=0.82) with use of the EHMRG7 model (area under the curve=0.81). The EHMRG30 had slightly lower (0.77) discrimination in comparison with EHMRG7. Another important key finding is the overestimation of 7-day and 30-day mortality at the low end of the risk spectrum by providers, and an underestimation of mortality at the higher end.
From the ED standpoint, 0% mortality at 7 and 30 days in the low-risk group is very reassuring. Emergency physicians' overestimation of risk in these same patients highlights the need for an objective score. Still, it would be good to know what element of the risk score drove categorization. Dichotomizing certain variables, such as emergency medical services transport (at times inappropriately used in the United States) and troponin (how positive?), may sway the risk rule. Using an online EHMRG calculator, it is possible to categorize patients with either a systolic blood pressure of 80 mm Hg, a very high troponin value, or significantly worse acute kidney injury into the low-risk group. This brings the challenge of real-world applicability into the crosshairs; for the decision rule to be used, it must account for patients who clearly need admission, but are categorized by the risk score as low risk. This is arguably unfair to the decision rule and discounts the rigor by which this rule was developed. Furthermore, it renders clinical judgment obsolete. Nevertheless, it highlights the need for an implementation study. The absence of high-risk features in EMHRG suggests a lower-risk patient; how- 
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Clinical Validation ever, they still may not be eligible for discharge because of other complicating and competing conditions. This study advances our understanding of the EHMRG rule, and risk stratification in general, but there are several limitations to consider. Nearly 30% of patients have no history of heart failure. Although management of de novo heart failure varies country by country, in the United States such patients generally warrant admission. The need for decongestion, identification, and management of precipitants, and investigating underlying cardiac structure and function, as well, is challenging to accomplish outside of the hospital setting. Similarly, how well does the model discriminate when high-risk patients are excluded? A risk rule for discharge has less utility in patients with hypotension, who require noninvasive or invasive ventilation, have very high troponin values, or have severe acute kidney injury. Once all the appropriate reasons to admit are taken out, how then do we decide what to do? Data collection was not standardized, and this can introduce inconsistency and inaccuracies. The authors discuss the use of a net reclassification index to suggest how the EHMRG rule could impact physician decision making. However, this may not be a completely accurate picture of the rule's impact. Although there is a clear need to identify lower-risk patients safe for ED discharge, provider decision-making accounts for the possible success of outpatient management given the severity of both AHF and non-AHF symptoms. Finally, the standard work-up in the participating EDs did not routinely include the use of natriuretic peptides or an ECG. Natriuretic peptides have been found in other risk models to be an important variable in risk stratification. 7, 10 Are we any closer to the holy grail of safe ED discharge based on an AHF risk rule? The EHMRG rule uses readily available data to stratify patients into lowrisk and very-low-risk categories. It has been derived and externally tested in large cohorts of patients. The next logical step is to incorporate natriuretic peptides into the rule and test the additive value of this rule alongside provider risk estimation in a large randomized trial that includes a population of patients across the spectrum of disease severity throughout the United States and Canada.
However, establishing a risk rule is just one component needed to change the current ED approach to disposition decision making. 15 Early, aggressive treatment is also necessary so that patients experience adequate symptom relief. Waiting to provide treatment until after the work-up is complete, or not providing sufficient treatment, introduces unnecessary delays, fails to provide sufficient symptom relief, and could prevent ED discharge. Once appropriately treated and risk stratified, a reliable mechanism for early outpatient follow-up is mandatory. Some patients with AHF in the ED will have an established patient-provider relationship in which outpatient follow-up is easily facilitated. However, rapid outpatient access for all patients regardless of the time of ED discharge and previous provider relationship is crucial for success.
Over the next decade there are great opportunities to increase the proportion of patients with AHF in the ED who can be safely discharged home. Although such needed progress is unlikely to match the state of disposition decision-making in other cardiovascular processes in the ED, such as chest pain, studies such as ACUTE (Acute Congestive Heart Failure Urgent Care Evaluation) are a necessary step in the right direction. Other AHF rules require similar external testing and implementation studies to determine their optimal role in the ED. Such continued advances will help drive further improvements in early treatment and local support for rapid outpatient follow-up: necessary items to safely discharge a larger proportion of patients with AHF. 
ARTICLE INFORMATION Correspondence

Disclosures
Dr Collins reports research support received from National Institutes of Health, Agency for Healthcare Research and Quality, American Heart Association, Patient-Centered Outcomes Research Institute, and Ortho Clinical; consulting fees received from Novartis, Medtronic, Ortho Clinical, and Vixiar. Dr Pang was supported by Grant R01HS025411 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. Dr Pang was also supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award R34HL136986. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. He also has received honoraria/ consulting fees/research support from Roche Diagnostics, BMS, and Novartis.
